Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1
- A Multi-Center, Double-Blind, Parallel-Group Study to Eval. Short-Term Safety and Efficacy and Long-Term Main.....
- A Multi‐Center, Double‐Blind, Randomized, Placebo‐Controlled, Study of Treatment of Binge Eating Disorder
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled2-Way Crossover Study of the Efficacy and Safety Of........
- A Multi-Center, Non-Randomized Trial to Determine the Safety& Effectiveness of the Model400 Aortic Valve Bioprosthesis..
- A Multi-Center, Open-Labe, Single-Arm Study Assessing Dyad (Subject and Caregiver) Perception F Convennience and Prefere
- A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment Of.....
- A Multi-Center, Open-Label Study of the Human Anti-Tnf Monoclonal Antibody Adalimumab to Evaluate the Long-Term
- A Multi-Center, Open-Label Treatment Protocol of the Human Anti-Tnf Monoclonal Antibody Adalimumab in Patients......
- A Multi-Center, Open-Label, Single-Arm, Phase 3B Study of Macitentan in Patients With Pulmonary Arterial Hypertensio..
- A Multi-Center, Open-Labeled Study to Investigate the Pk Lacosamide (Lcm) Oral Formulation As Therapy in Children
- A Multi-Center, Phase II Trial Evaluating High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell
- A Multi-Center, Phase Iib, Randomized, Placebo-Controlled, D/B Study of the Effects of N-Acetylcysteine on Redox Change
- A Multi-Center, Placebo Controlled, Double-Blind Trial to Examine Safety...of ACP-103 In...of Psychosis in Pd
- A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients with HCV Genotypes 2 or 3
- A multi-center, placebo-controlled, dose-ranging evaluation of the safety and efficacy of OP2000 administered once daily by subcutaneous injection for the treatment of active Crohn’s disease
- A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment
- A Multi-Center, Prospective, Randomized, Double-Blind, Placeplacebo-Controlled Phase III Clinical Outcome Study To......
- A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic
- A Multi-Center, Randomized, Double-Blind Clinical Trail to Evaluate the Sfaety and Tolerability of 24 Weeks Treatment Wi
- A Multi-Center, Randomized, Double-Blind Five-Way Crossover Pharmacodynamic Study Comparing Perrigos Albuterol .........
- A Multi-Center, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin...
- A Multi-Center, Randomized, Double-Blind, Active-Controlled Clinical Trial to Evalate the Safety and Tolerability.......
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlledand Open-Label...Atorvastatin Plus Amlodipine When Compared
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlledparallel Group Study of the Efficacy, Safety, ..............
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlledsequential Dose Escalation, Safety, Tolerability, and Pre...
- A Multi-Center, Randomized, Open Label Study to Evaluate Thesafety, Tolerability and Efficacy of Albuferon....
- A Multi-Centered, Double Blind, Randomized, Active Referenceparallel Group Study
- A Multi-Centre, Open Label Extension Sutdy to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 As An
- A Multi-Ctr Phase Ii Stdy to Assess the Saf and Preliminary Efficy of Multiple Doses of Inh-A21, a Donor-Selected Human St